Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 8(1): 4859, 2018 03 20.
Article in English | MEDLINE | ID: mdl-29559666

ABSTRACT

Fusarium proliferatum (F. proliferatum) is known as a pathogen of corn and other crops, but its role in fungal keratitis has not been well investigated. Among 877 Fusarium isolates, we identified 155 (17.7%) stains as F. proliferatum according to their morphological features and partial DNA sequencing of translation elongation factor-[Formula: see text] (EF-[Formula: see text]) in this study. In vitro antifungal susceptibility tests showed that the F. proliferatum strains were sensitive to natamycin and vorionazole but resistant to amphotericin B, fluconazol, ketoconazole and itaconazole. Most of the F. proliferatum-positive keratitis patients (44/155,28.4%) were aged 51-60 years old. The main cause of infection was injury by a plant (51/155, 32.9%). A combination of 1% amphotericin B and 3% ketoconazole cured 45.2% (14/31) and a combination of 0.5% natamycin and 0.5% voriconazole cured 59.1% (13/22) of F. proliferatum-positive patients. The date suggests that F. proliferatum identified through EF-1ɑ DNA sequencing is an important new species that causes fungal keratitis. Based on antifungal susceptibility, treatment with a combination of 0.5% natamycin and 0.5% voriconazole improves the therapeutic efficacy in F. prolifertum-positive patients.


Subject(s)
Antifungal Agents/therapeutic use , Corneal Ulcer/drug therapy , Eye Infections, Fungal/drug therapy , Fusariosis/drug therapy , Fusarium/genetics , Natamycin/therapeutic use , Voriconazole/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Child , Corneal Ulcer/microbiology , Corneal Ulcer/pathology , Drug Therapy, Combination , Eye Infections, Fungal/pathology , Female , Fusarium/classification , Fusarium/cytology , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Ophthalmic Solutions/therapeutic use , Peptide Elongation Factor 1/genetics , Sequence Analysis, DNA , Treatment Outcome , Young Adult , Zea mays/adverse effects , Zea mays/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL
...